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Abstract
Background: The apical junctional complex (AJC) is a dynamic structure responsible to maintain
epithelial cell-cell adhesions and it plays important functions such as, polarity, mechanical integrity,
and cell signaling. Alteration of this complex during pathological events leads to an impaired
epithelial barrier by perturbation of the cell-cell adhesion system. Although clinical and
experimental data indicate that prostaglandin E2 (PGE2) plays a critical function in promoting cell
motility and cancer progression, little is known concerning its role in AJC disassembly, an event
that takes place at the beginning of colorectal tumorigenesis. Using Caco-2 cells, a cell line derived
from human colorectal cancer, we investigated the effects of prostaglandin E2 (PGE2) treatment on
AJC assembly and function.
Results: Exposition of Caco-2 cells to PGE2 promoted differential alteration of AJC protein
distribution, as evidenced by immunofluorescence and immunoblotting analysis and impairs the
barrier function, as seen by a decrease in the transepithelial electric resistance and an increase in
the permeability to ruthenium red marker. We demonstrated the involvement of EP1 and EP2
prostaglandin E2 receptor subtypes in the modulation of the AJC disassembly caused by prostanoid.
Furthermore, pharmacological inhibition of protein kinase-C, but not PKA and p38MAPK
significantly prevented the PGE2 effects on the AJC disassembly.
Conclusion: Our findings strongly suggest a central role of Prostaglandin E2-EP1 and EP2 receptor
signaling to mediate AJC disassembly through a mechanism that involves PKC and claudin-1 as
important target for the TJ-related effects in human colorectal cancer cells (Caco-2).
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Tight junctions (TJs) and the subjacent adherens junctions
(AJs) constitute the apical junctional complex (AJC),
which is responsible to maintain the epithelial phenotype
[1,2]. TJs form a semi-permeable diffusion barrier in an
ion- and size- selective manner through the paracellular
pathway and have a fence function to maintain cell polar-
ity as a boundary between the apical and basolateral
plasma membrane domains [3]. AJs are the main adhesive
junctions involved in the mechanical strength of tissues
[4]. Recent studies suggest that these complexes not only
mediate cell-cell adhesion, but are also engaged in signal
transduction [5]. E-cadherin, the main protein of AJs
interacts with the cytoskeleton via association with cyto-
plasmic proteins, the α-, β – and p120-catenins. Whereas
β-catenin associated with E-cadherin at the plasma mem-
brane regulates cell-cell adhesion, cytoplasmic β-catenin
is involved in signal transduction and activation of genes,
which play important roles in the development and pro-
gression of colorectal carcinoma [6]. The role of TJ pro-
teins is less understood in this context. A number of
integral membrane proteins associated with TJs have been
identified during recent years. These include occludin,
junctional adhesion molecule (JAM) and the claudin fam-
ily consisting of at least 24 members. PDZ proteins of the
MAGUK family are other integrant proteins of TJs, which
are localized at the membrane-cytoskeleton interfaces of
cell-cell contacts. They include the zonula occludens pro-
teins ZO-1, ZO-2 and ZO-3, which are potentially
involved in cell signaling [7,8]. The role of ZO-1 protein
is related to the interaction with the transcriptional factor
ZONAB, known to regulate many events such as growth
and proliferation [9].
Prostaglandins (PGs) are bioactive lipid molecules pro-
duced by the cyclooxygenase enzymes COX-1 and COX-2,
and exert diverse physiological actions in the gastrointes-
tinal tract including maintenance of mucosal integrity,
regulation of secretion and cell motility [10]. Clinical and
experimental data indicate that prostaglandin E2 (PGE2)
plays a predominant role in promoting cancer progres-
sion. It was reported that PGE2 stimulates EP receptor sig-
naling with subsequent enhancement of cellular
proliferation, promotion of angiogenesis, inhibition of
apoptosis, stimulation of invasion/motility of colon can-
cer cells, as well as tumorigenic potential in intestinal epi-
thelial cells [11,12]. It has been reported that both COX-2
and the epidermal growth factor receptor (EGFR) are acti-
vated in most human cancers. The observation that forced
expression of COX-2 in human colorectal cancer (CRC)
cells stimulates proliferation through EGFR activation,
suggests the likelihood of a cross talk between these two
pathways [13,14]. In a previous study we have demon-
strated a link between the PKC, EGFR and MAPK path-
ways to modulate the loss of E-cadherin dependent cell-
cell adhesion in Caco-2 cell [15].
PGE2 has also been implicated in direct EGFR activation
through intracellular phosphorylation of receptor tyro-
sine kinase or extracellular release of a membrane-bound
EGFR ligand, such as heparin-binding EGF in human
colorectal cancer cells [16]. However, the involvement of
EP receptor subtypes in these studies has been not
reported. Furthermore, it was shown in LS174T, a human
colorectal cancer cell line, that PGE2 induces expression of
amphiregulin, an EGFR ligand, through a Protein Kinase
A (PKA)-dependent mechanism [11]. Although it is
known that PGE2 is the ligand to four EP receptors sub-
types called EP1, EP2, EP3 and EP4, which are the prod-
ucts of separate genes [17,18], the lack of information
concerning the role that each EP receptor plays hinders
the understanding of PGE2-mediated gastrointestinal
physiology alterations. Moreover, the precise role of each
EP in the malignant behavior remains to be defined. Some
studies have reported the participation of the EP1 and EP4
receptor in promoting tumorigenic behavior in colon car-
cinogenesis [12,19,20] and downregulation of subtype
EP3 during colon cancer development [21]. However, the
identification of EP modulating epithelial barrier function
through mediation of AJC disassembly events has not
been reported.
The aim of the present study was to investigate the
response of Caco-2 cells to treatment with PGE2. We
hypothesized that PGE2 would impair the AJC assembly
and function of Caco-2 cells. We examined AJC protein
distribution, paracellular permeability and identified the
involvement of EP receptors as well as cell signaling path-
ways in response to prostanoid treatment. We report in
this study that treatment with PGE2 caused a transient AJC
disassembly through a network involving EP1 and EP2
receptors and PKC signaling with claudin-1 as target
related to TJs effects in the human colon cancer cells,
Caco-2.
Results
Prostaglandin E2 treatment causes a differential 
redistribution of the AJC proteins
Initially, we analyzed the distribution of the AJC proteins
after treatment with PGE2 by immunofluorescence micro-
scopy using antibodies against E-cadherin, β-catenin,
claudin-1, occludin and ZO-1. Figure 1 shows a continu-
ous and intense labeling at the cell-cell contact region for
all proteins used in non-treated cells. After PGE2 treat-
ment, it was possible to observe alterations in the immu-
nostaining pattern of AJC proteins with exception of ZO-
1 that remained at the membrane. After 15 min of treat-
ment E-cadherin appears in a discontinuous and irregularPage 2 of 13
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BMC Cell Biology 2008, 9:63 http://www.biomedcentral.com/1471-2121/9/63string-of beads-shape at the cell-cell contacts. At 30 min
internalization into the cytoplasm was observed but at 60
min there was a significant recovery of the labeling pat-
tern. β-catenin at 15 min also showed a discontinuous
and irregular labeling at the membrane with projections
to the cytoplasm; at 30 min and 60 min of treatment it
appears with minor translocation into the cytoplasm,
however a considerable amount of the protein was still at
the membrane. Immunostaining of claudin-1 at 15 min
showed a discontinuous membranous staining in same
Prostaglandin E2 treatment causes a differential redistribution of the AJC proteinsFigure 1
Prostaglandin E2 treatment causes a differential redistribution of the AJC proteins. Caco-2 cells were grown on 
sterile glass coverslips and after PGE2 treatments they were processed for immunofluorescence analysis using specific antibod-
ies of AJC proteins, as indicated. Images show control (0 min) and treated for 15, 30 and 60 min treatments with 1 μM PGE2. 
Note that – with the exception of ZO-1 – E-cadherin, β-catenin, claudin-1 and occludin showed alterations of the staining pat-
tern at 15 and 30 min of treatment. An apparent recovery of the labeling was observed at 60 min for E-cadherin, β-catenin and 
claudin-1, but not for occludin that showed membranous projections to the cytoplasm. Bar: 10 μmPage 3 of 13
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more evident with strong points of labeling and a weak or
absent staining in the cell-cell contact area. At 60 min
there was a labeling recovery at the cell-cell contacts.
Occludin appears with no alterations at 15 min, however
after 30 and 60 min of treatment projections in the direc-
tion of the cytoplasm mainly at 60 min, were observed.
We further analyzed the subcellular distribution of AJC
proteins by immunoblotting using soluble and insoluble
TX-100 fractions after PGE2 treatment (Figure 2). The dis-
tribution pattern and densitometry analysis of the AJ pro-
teins, β-catenin, and E-cadherin showed a significant
translocation from the insoluble fraction to the soluble in
cells that were treated for 15 min with PGE2 (Figures 2A
PGE2 treatment alters the TX-100 solubility of AJC proteins in Caco-2 cellsFigure 2
PGE2 treatment alters the TX-100 solubility of AJC proteins in Caco-2 cells. Representative immunoblots and densi-
tometric analysis of E-cadherin (A), Beta-catenin (B), claudin-1 (C) and occludin (D) of insoluble (I) and soluble (S) fractions in 
Triton X-100 of cells that were untreated (0 min) or treated for 15, 30 and 60 min with 1 μM PGE2. In each case the score was 
calculated using the following equation: Arbitrary score= (amount of the protein in the soluble fraction)/(amount of the protein 
in the insoluble fraction). The score for untreated cells (0 min) was normalized as 1 in each case. Average scores S.E.M of three 
independent experiments are shown. Significantly different: * (P < 0.05).Page 4 of 13
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PGE2 treatment influences the AJC ultrastructural characteristics of Caco-2 cellsFigure 3
PGE2 treatment influences the AJC ultrastructural characteristics of Caco-2 cells. Caco-2 cells were grown on 
Transwell filters until they achieved confluence, treated with 1 μM PGE2 and processed for electron microscopy analysis. Rep-
resentative images of thin sections of control cells (A) shows an intact AJC between two neighbor cells, however cells treated 
with PGE2 for 15 (B), 30 (C) and 60 (D) show alterations in the AJC region, mainly at the adherent junction area. Note that the 
TJ (Arrowheads) apparently remain unaltered. Bar: 2.5 μm. TJs: Tight Junctions.
BMC Cell Biology 2008, 9:63 http://www.biomedcentral.com/1471-2121/9/63and 2B, respectively). In a similar manner, this same effect
was observed for the TJ proteins, claudin-1 but not for
occludin (Figures 2C and 2D). Together these results indi-
cate that PGE2 treatment caused a differential redistribu-
tion of the AJC proteins.
PGE2 induce ultrastructural AJC alterations with 
concomitant loss of TJ functionality
We examined morphological alterations of AJC caused by
PGE2 treatment using transmission electron microscopy
(Figure 3). Non-treated Caco-2 cells form a well-organ-
ized monolayer with a typical junctional complex in the
apical region and exhibit numerous microvilli (Figure
3A). When cells were exposed to 1 μM of PGE2, wide
spaces at the sub apical cell-cell contact region were visible
after 15 and 30 min and at 60 min there was an apparent
recovery of the AJC. Although alterations well pro-
nounced at the AJ area was observed, the TJ region appar-
ently remained intact during the PGE2 treatment (Figures
3B, C and 3D).
In order to verify TJ functionality after PGE2 treatment, the
epithelial barrier function was assessed in individual cell
junctions, using the ruthenium red technique and elec-
tron microscopy and in the cell monolayers by monitor-
ing the TER. As seen in Figure 4, ruthenium red added to
the apical region did not permeate through the TJs of
untreated cells, but it permeated through the paracellular
space in cells treated with PGE2, both at 15 and 30 min.
Next, the permeability to ions of confluent Caco-2 cells
was assessed by TER measurements, which showed a value
of about 400 Ω.cm2 (100%) in untreated cells. However,
PGE2 treatment caused a significant drop of the TER (41%
and 36%) after 15 and 30 min, respectively, but after 60
and 120 min there was a recovery. Additionally, using 16,
16-dimethyl Prostaglandin E2 (16, 16-dm PGE2), a syn-
thetic analogue of PGE2, we confirmed similar effects to
those observed when cells were treated with PGE2 (Figure
4B).
Identification of Prostaglandin E2 Receptor Subtypes EP 
involved in the AJC disassembly
PGE2 is known to interact with four different types of cell
surface prostaglandin E receptors (EP1, EP2, EP3 and
EP4), which in turn activate different signaling pathways
[10]. In the present study we identified PGE2 Receptor
Subtypes EP involved in AJC disassembly using butaprost,
an EP2 specific receptor agonist and sulprostone and 17-
phenyl trinor, both EP1 and EP3 agonist receptors and by
TER measurements (Figure 5). Butaprost, sulprostone and
17-phenyl trinor were seen to cause a significant TER
decrease after 15 and 30 min of treatment when compared
to non-treated cells, however after 60 and 120 min there
was a reverse effect on the TER measurements. It is impor-
tant to emphasize that although sulprostone and 17-phe-
nyl trinor PGE2 are EP1 and EP3 receptor agonists, in the
concentration here used (1 μM), they have a higher affin-
ity for the EP1 receptor [22-24]. This result was similar
when the cells were treated with PGE2 or with its ana-
logue, (16, 16-dm PGE2), which indicates the involve-
ment of EP1 and EP2 receptors in a transient AJC
disassembly mediated by PGE2.
PGE2 module AJC disassembly through PKC signaling
There are no data about the cell-cell adhesion mecha-
nisms mediated by PGE2, nor information concerning the
signaling pathways involved in this event Thus, we
decided to investigate downstream cell signaling mecha-
nisms triggered by the EP receptors after PGE2 treatment
(Figure 6). When cells were pretreated with SB203580, an
inhibitor of p38 MAPK, it was possible to observe that the
inhibitor did not prevent the drop of the PGE2- induced
TER. Incubation of Caco-2 cells with H-89, a PKA blocker,
did not prevent the TER decrease after 15 and 30 min of
PGE2 treatment, but abolished the gradual TER re-stabili-
zation promoted after 60 and 120 min. It is important to
point out that, although the IC50 of H-89 for PKA is 48 or
135 nM [25], we used the concentration of 20 μM on the
basis of previous studies showing that it is also able to
inhibit PKA activity in culture cells [26,27]. Next, we veri-
fied if PKC is involved in this event and observed that pre-
treatment with Calphostin C, a well-known inhibitor of
novel and conventional PKC isoforms, prevented the TER
drops at all assessed times (Figure 6A). We further con-
firmed this later result by immunoblotting and immun-
ofluorescence analysis using claudin-1, a TJ protein
known to be involved in the regulation of the paracellular
permeability [28]. Figures 6B and 6C show the reversible
effect on the translocation to the TX-soluble fraction and
redistribution of this protein through pretreatment with
Calphostin C prior to incubation for 15 min with PGE2. In
parallel, we also verified the effect of Calphostin C on the
ultrastructural status of the AJC and TJ functionality using
the ruthenium red marker. In Figure 6D it is possible to
see that pretreatment with the PKC inhibitor completely
blocked the permeation of the marker through the para-
cellular space caused after treatment for 15 and 30 min
with PGE2. The ruthenium red in cells pretreated with Cal-
phostin C was restricted at the apical region in a similar
manner as in untreated cells. Taken together these results
indicate that PKC is involved in the modulation of the AJC
disassembly in PGE2- stimulated Caco-2 cells.
Discussion
The loss of the AJC assembly by deleterious inflammatory
mechanisms is an important problem in intestinal physi-
ology due to the contribution of this structure to the
maintenance of cell-cell adhesion. PGE2 has been impli-
cated in essential physiological processes in the colon
such as electrolyte transport, cell motility and in thePage 6 of 13
(page number not for citation purposes)
BMC Cell Biology 2008, 9:63 http://www.biomedcentral.com/1471-2121/9/63pathogenesis of inflammatory bowel diseases where
increased levels of PGE2 are observed in inflamed tissue
[17]. Also, PGE2 has been reported as having a role in
intestinal tumorigenesis [29]. Thus, there is strong evi-
dence indicating a link between AJC regulation, intestinal
inflammation and tumorigenesis. However the mecha-
nisms underlying the PGE2 effects on AJC disassembly, a
pivotal event at the beginning of the colorectal tumorigen-
esis, remain to be elucidated.
The results reported here show that PGE2 treatment
caused transient differential redistribution of the AJC pro-
teins in Caco-2 cells. We observed, by immunofluores-
cence, that AJ proteins, β-catenin and E-cadherin undergo
significant alteration in localization. Similarly, TJ proteins
claudin-1 and occludin showed an apparent redistribu-
tion from cell-cell contacts to the cytoplasm; however ZO-
1 remained unaltered. By immunoblotting it was possible
to observe a significant increase in the soluble TX-100
PGE2 affect the paracellular permeability in Caco-2 cellsFigure 4
PGE2 affect the paracellular permeability in Caco-2 cells. Cells were cultured on Transwell polycarbonate filters and 
the TJ functionality was analyzed by the ruthenium red technique (A) and by measuring the Transepithelial electrical resistance 
(TER) (B). A: Representative images of thin sections of control cells showing the ruthenium red in the apical region in control 
cells and in cells treated with PGE2, as indicated. Cells incubated with the prostanoid revealed extensive spaces in the junc-
tional complex area and permeation of the marker between the intercellular spaces. Bar: 0.8 μm. Arrowheads: ruthenium red. B. 
TER was measured in different conditions as indicated. Observe that PGE2 and its analogue, PGE2 16-16 dm PGE2, caused a sig-
nificant drop of the TER (*P < 0.01 compared with untreated cells). The effect was visible at 15 and 30 min, however at 60 and 
120 min a recovery of the TER was observed.Page 7 of 13
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for occludin. Furthermore, electron microscopy analysis
of the subapical AJC region revealed wide spaces in this
area in response to PGE2, but the TJ regions apparently
remained unaltered. Concomitantly to these results, we
showed a significant decrease of the TER, as well as
increased permeation to ruthenium red marker in cells
treated with PGE2. Since TJs are largely responsible for reg-
ulating paracellular permeability [30-32] it is probably
that PGE2 acts directly against the components of these
structures. The distribution analysis of claudin-1 tends to
support this conclusion, since the translocation of this
protein from the TX-100 insoluble fraction (cytoskeleton-
linked proteins) to the TX-100 soluble fraction (cytoplas-
mic proteins) is associated with the drop of the TER and
permeation to ruthenium red in response to PGE2. Several
groups have described the involvement of pro-inflamma-
tory cytokines, such as TNFα and interferon-γ , on AJC
proteins and barrier function modulation [33,34]. In rela-
tion to PGE2, only one study carried out by Martin-Ven-
egas et al., [35] reported increased paracellular
permeability when differentiated Caco-2 cells were stimu-
lated with PGE2. Nevertheless, in this study the AJC pro-
tein distribution was not carried out, different PGE2
concentrations were used and paracellular permeability
alteration was only evidenced after 2 h of treatment. In
our work here we also reported altered cytoskeleton-
linked claudin-1, as evidenced by their translocation to
TX-100 soluble fraction in PGE2-treated cells, corroborat-
ing with the paracellular permeability alteration. This
result is consistent with studies showing that alterations in
distribution or expression of claudin-1 play an important
role in epithelial barrier function [36-38]. Adaptor ZO
proteins have been documented as being responsible for
the connection between claudins and the actin cytoskele-
ton [7]. The fact that we did not find distribution differ-
ences of ZO-1 in PGE2- treated cells, suggests that other
adaptor proteins, not investigated here, could be mediat-
ing this linkage.
Prostanoids such as PGE2 exert their biological action
through binding to four specific membrane receptors –
the subtypes EP1 to EP4 that are G protein-coupled recep-
tors [29]. The expression and involvement of these recep-
tors in colorectal cancer has been reported [19,20,29];
however it is not known whether these receptors are
Effects of EP agonists on the transepithelial electric resistanceFigure 5
Effects of EP agonists on the transepithelial electric resistance. Caco-2 cells were grown to confluence on Transwell 
polycarbonate filters and the TER was measured before and after treatment with agonists. All the agonists caused a drop of the 
TER at 15 and 30 min and at 60 and 120 min a recovery was observed. S.E.M of three independent experiments are shown. Sig-
nificantly different: * (P < 0.05).Page 8 of 13
(page number not for citation purposes)
BMC Cell Biology 2008, 9:63 http://www.biomedcentral.com/1471-2121/9/63
Page 9 of 13
(page number not for citation purposes)
PKC inhibition reverts the effect on the redistribution of Claudin-1 and the paracellular permeability caused by PGE2Figure 6
PKC inhibition reverts the effect on the redistribution of Claudin-1 and the paracellular permeability caused 
by PGE2. The TER was measured before and after treatment with 1 μM PGE2 and pretreated for 1 h with H-89, SB203580 and 
Calphostin C. Note that the decrease of the TER was PKC-dependent and H-89 abrogated the TER recovery at 60 and 120 
min (A). Caco-2 cells were grown until confluence treated or pretreated with Calphostin C, prior to incubation with 1 μM 
PGE2and the redistribution of Claudin-1 was assessed by immunoblotting (B) and immunofluorescence (C). The effect of pre-
treatment with the inhibitor was also analyzed by using the ruthenium red technique and electron microscopy (D). Observe 
that PKC inhibition was able to block alterations caused by PGE2. Bars in B: 10 μm and in D: 1.2 μm.
BMC Cell Biology 2008, 9:63 http://www.biomedcentral.com/1471-2121/9/63involved in the regulation of the AJC disassembly and
consequently contribute to carcinogenesis colorectal.
Here, we showed the involvement of PGE2 receptor sub-
types EP1 and EP2 in mediating AJC disassembly. This
hypothesis is supported by the observation that 17-phenyl
trinor PGE2, butaprost, and sulprostone caused a signifi-
cant decrease in the TER at 15 and 30 min in a similar
manner to PGE2 and its analogue. It has been reported
that both, sulprostone and 17-phenyl trinor PGE2 are EP1
and EP3 receptor agonists, however in the concentration
of 1 μM used in the present study, they have a higher affin-
ity for the EP1 receptor [22,39,40]. Since previous results
show that Caco-2 cells express only EP1 and EP2 subtypes
of PGE2 receptors [41], we suggest that PGE2 mediates AJC
disassembly through EP1 and EP2 receptors in this cell
line.
It is known that EP2 receptors are coupled to PKA/adenyl
cyclase and mediate the increase of intracellular cAMP
[41] whereas ligand binding of EP1 is associated with
phospholipase C and PKC activation [42]. On the other
hand, studies have demonstrated the involvement of var-
ious cell signaling pathways such as: PKC, PKA, MAPK,
and PI3K/Akt in the regulation of the TJ barrier function
[7]. In our PGE2 stimulation model using Caco-2 cells, we
found that PGE2-EP1 and -EP2 receptor signaling to
decrease TER was predominantly linked to the PKC path-
way, but not to PKA or p38MAPK. It is known that PKC
has long been recognized to affect epithelial and endothe-
lial barriers. This kinase consists of a family of Ser/Thr-
specific kinases, which includes 12 known isozymes that
can be classified into three subfamilies: conventional (α,
β1, β2 and γ ), novel (δ, ε , θ, ε  and μ) and atypical (λ, τ
and ζ), which differ in their mechanism of action, subcel-
lular distribution, substrate type and expression [7]. In
addition, several studies using different agents that per-
turb the epithelial junctional complex have demonstrated
the involvement of various kinases in the phosphoryla-
tion and regulation of claudin proteins, however the
mechanisms underlying this effect remain largely
unknown. In relation to PKC, a recent study using three
complementary molecular approaches and Caco-2 cells
showed that the PKC-θ isoform plays various novel mech-
anisms in intestinal epithelium, namely: alterations of the
claudin-1 and claudin-4 isotypes phosphorylation, mem-
brane assembly, and distribution as well as permeability
function in cell monolayer [38]. If this PKC isoform is
responsible to mediate alteration in claudin-1 in Caco-2
cells treated with PGE2, remain to be elucidated. It is an
important addition to studies on cell signaling mecha-
nisms involving EP receptors in colorectal cancer that are
usually aimed at analysing proliferation or apoptosis
events, but not epithelial cell barrier function. For
instance, it was reported that in an EP4 receptor expres-
sion model with HEK293 cells, cAMP signalling appears
to play a minor role in proliferation [41]. By contrast,
cAMP-dependent suppression of apoptosis by PGE2 seems
to occur by a mechanism dependent on ERK and
p38MAPK signaling, but not PKA [43]. Also, PGE2-
dependent EGFR activation in human colorectal cancer
cells appears to be variable, with responsive (LS-174) and
unresponsive (DLD-1) cell lines described [16,44].
Recently, using a model of EP4 receptor overexpression in
HT-29 cells, it was shown that PGE2-EP4 receptor signal-
ing was linked predominantly to cAMP signaling and in
low level to ERK activation, but not PKB/AKT signaling
[20]. There is a clear significant heterogeneity of signaling
pathways mediating PGE2 activities in different colorectal
cells and the interplay between EP receptor subtypes,
which are variably present on different colorectal cancer
cell lines, may explain this event. Interestingly, we did not
find PKA involvement in TER decrease, however it is rec-
ognized that cAMP can also signal in a PKA-independent
manner via the cAMP-dependent guanine nucleotide
exchange factor Epac1, which in turn activates Ras-GTPase
Rap1 [45]. Additional studies are needed to elucidate if
Epac 1 is involved in EP1 and EP2 receptor signaling path-
ways mediated by PGE2. Moreover, the fact that H-89 did
prevented TER recovery after 60 and 120 min of treatment
with PGE2, suggests that PKA activation is necessary for
AJC restoration, which is consistent with data showing
that PKA is related to positive regulation of cell-cell and
cell-substrate adhesion [46].
In summary, we have shown that PGE2 can affect AJC
architecture and function and that at least part of this
effect is mediated through PKC activation in an event that
requires the participation of EP1 and EP2 receptors and
claudin-1 as an important target of PKC for the TJ-related
effects.
Conclusion
In this study we analyzed cell signaling mechanisms
underlying PGE2 treatment on the Apical Junctional
Complex assembly and function in a human colon can-
cer cell model. Using a physiologically relevant prosta-
noid dose it was possible to observe that AJC proteins are
differentially redistributed and this effect was concomi-
tant to an impairment of the paracellular permeability in
Caco-2 cells. We demonstrated for the first time that
PGE2-EP1 and EP2 receptor signaling regulates AJC dis-
assembly through a mechanism that involves PKC, but
not PKA or p38MAPK and reveals a critical role of clau-
din-1 in this event. Examination of these pathways can
give a better understanding of the mechanisms concern-
ing the loss of cell-cell adhesion and colon cancer pro-
gression and suggest new directions for potential therapy
for this disease.Page 10 of 13
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Antibodies and reagents
Rabbit polyclonal anti-claudin-1 (JAY.8), occludin and
ZO-1 (Z-R1) antibodies were purchased from Zymed Lab-
oratories, Inc. (San Francisco, CA, USA). Mouse mono-
clonal anti-E-cadherin (36) was purchased from BD
Biosciences (San Diego, CA, USA). The rabbit polyclonal
anti-beta-catenin was purchased from Sigma Chemical
Co. (St Louis, MO, USA). The secondary antibodies Alexa
488-conjugated goat anti-rabbit IgG and Alexa 546-conju-
gated goat anti-mouse IgG were purchased from Molecu-
lar Probe (Eugene, OR). Peroxidase-conjugated goat anti-
rabbit IgG were obtained from Zymed Laboratories, Inc.
(San Francisco, CA, USA) and peroxidase-conjugated goat
anti-mouse IgG from Sigma. Prostaglandin E2, butaprost,
sulprostone, 16, 16-dm PGE2 and 17-phenyl trinor PGE2
were purchased from Cayman Chemical Company, (Ann
Arbor, MI). SB203580, H-89 and Calphostin C were pur-
chased from Biomol Res. Labs. Inc. (Plymouth Meeting,
PA).
Cell culture
Caco-2 cells (ATCC, # HTB-37, Rockville, MD, USA), a
human colon cancer cell line were grown in Dulbecco
Modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), penicillin G (60 mg/l) and
streptomycin (100 mg/l) at 37°C in humidified atmos-
phere of 5% CO2/air. Culture medium was changed every
24 h to avoid nutrient depletion. All experiments were car-
ried out when cells achieved confluence.
PGE2 and EP2 agonist treatments
In order to determine the concentration of PGE2 in our
experiments and on the basis of a kinetic study used by Pai
et al [13], initially doses of 0.1 and 1 μM were tested. We
determined that 1 μM was the concentration able to cause
significant alterations on the AJC and was used in all sub-
sequent experiments. Cell monolayers were serum-starved
for 24 h then treated with 1 μM PGE2 for 15, 30 and 60
min. When indicated, cells were pre-treated with specific
inhibitors of p38 MAPK (10 μM SB203580), PKA 20 μM
(H-89) and PKC (500 nM Calphostin C), prior to PGE2
treatment.
The involvement of Prostaglandin E2 receptor EP subtypes
was analyzed by using 1 μM butaprost, EP2 agonist recep-
tor, and the EP1 and EP3 agonist receptors: 1 μM sulpros-
tone and 1 μM 17 phenyl trinor PGE2. We used also 1 μM
16, 16-dimethyl Prostaglandin E2 (16, 16-dm PGE2),
PGE2 analogous.
Transepithelial Electrical Resistance (TER)
It is well known that TER is an instantaneous measure-
ment that evaluates the degree of tightness and paracellu-
lar flux across epithelium [1]. In order to determine TJ
functionality after PGE2 and EP agonist receptor treat-
ments, we performed TER analysis at different times of
treatments. Caco-2 cells were grown on Transwell polycar-
bonate filters 0.4 μm pore size (Costar, Cambridge, MA,
USA) until confluent and treated as described above. TER
values were determined using a Millicel-ERS system (Mil-
lipore Co, Billerica, MA, USA), with a 20A constant cur-
rent. All TER values were normalized for the area of the
filter (0.6 cm2) and were obtained after background sub-
traction (i.e., filter and bath solution). The results are
expressed as percentage of total count (100%) values of
each treatment in relation to the control group of three
independent experiments.
Immunofluorescence Microscopy
Cell monolayers were grown on sterile glass cover slips.
After 15, 30 or 60 min of PGE2 treatment, cells were
washed in PBS supplemented with 100 mM CaCl2 (PBS/
CM), fixed and permeabilized with 100% methanol at -
20°C for 20 min. Subsequently, they were re-hydrated in
PBS/CM, incubated in blocking solution (0.2% BSA in
PBS/CM) for 1 h and overnight at 4°C with primary anti-
bodies anti-ZO-1 (1:25), anti-claudin-1 (1:25), anti-
occludin (1:20), anti- β-catenin (1:2000) and anti-E-cad-
herin (1:100). Afterward they were incubated for 1 h at
37°C with the secondary antibodies Alexa 488-conju-
gated goat anti-rabbit IgG (1:500) or with Alexa 546-con-
jugated goat anti-mouse IgG (1:500). The cover slips were
washed in PBS and mounted using n-propyl-gallate. Cell
staining was detected using an Axiovert S 100 immunoflu-
orescence microscope equipped with a CCD camera and
KS 300 image analyzer (Carl Zeiss Inc., Jena, Germany).
Transmission electron microscopy
Cells were cultured on Transwell polycarbonate filters,
and after treatments they were washed in PBS and fixed in
a solution containing 2.5% glutaraldehyde, 1% parafor-
maldehyde, 0.8% sucrose and 2 mM CaCl2 in 0.1 M
cacodylate buffer, pH 7.4. Post-fixation was carried out in
1% osmium tetroxide (OsO4) in cacodylate buffer, con-
taining 0.8% potassium ferrocyanide and 5 mM CaCl2 for
45 min. Subsequently, the cells were dehydrated with ace-
tone and embedded in Epon resin. Ultrathin sections (60
nm) were obtained, stained with uranyl acetate and lead
citrate and observed in a Zeiss CEM-900 transmission
electron microscope (Carl Zeiss Inc., Jena, Germany).
In order to determine TJ functionality, cell monolayers
were washed in PBS, and fixed for 60 min on the apical
side with the solution above indicated containing 6 mg/
ml of ruthenium red. Cells were washed three times with
cacodylate buffer containing ruthenium red for 10 min
each and post fixed with 1% OsO4 and 6 mg/ml ruthe-
nium red in cacodylate buffer for 45 min. Subsequently,
they were dehydrated in acetone series and embedded inPage 11 of 13
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3 min with lead citrate only and observed in a Zeiss CEM-
900 transmission electron microscope (Carl Zeiss Inc.).
Cell extraction in Triton X-100 and immunoblotting
Samples were rinsed three times in PBS/CM and incu-
bated for 20 min at 4°C in extraction buffer CSK: 50 mM
NaCl, 10 mM piperazine-1, 4-bis (2-ethanesulfonic acid)
(Pipes), pH 6.8, 3 mM MgCl2, 0.5% TritonX-100, 300 mM
sucrose, 1 mM orthovanadate, 20 mM NaF, and protease
inhibitor cocktail (1:100, Sigma Chemical Co.) for 20
min at 4°C. Cells were scratched from plates, homoge-
nized and centrifuged at 10,000 g for 10 min at 4°C. The
supernatant corresponding to the TX-100 soluble fraction
(cytosolic proteins) was removed and stored at -20°C. The
pellet was resuspended in SDS buffer: 20 mM Tris-HCl,
pH 7.5, 5 mM ethylenediamine-tetraacetic acid (EDTA),
2.5 mM [ethylenebis(oxyethylenenitrilo)] tetra (EGTA),
1% sodium dodecyl sulfate (SDS) and boiled at 100°C for
10 min. After centrifugation for 10 min at 10,000 g the
supernatant, corresponding to the TX-100 insoluble frac-
tion (cytoskeleton-linked proteins), was gently removed
and stored at -20°C.
Equal amounts of protein (30 μg), of cell fractions were
electrophoretically separated by SDS-PAGE in 7.5% or
12% gels and transferred to nitrocellulose sheets using a
semidry transfer cell (BioRad, Hercules, CA, USA) at 10 V
for 60 min. [47]. Then, the membranes were blocked for
1 h with TBS-T: 20 mM Tris-HCl, pH 7.6, 137 mM NaCl
and 0.1% v/v Tween 20, containing 5% low-fat dried milk
and incubated overnight with primary antibodies: anti-
occludin (1:250), anti-E-cadherin (1: 2,000), anti-clau-
din-1 (1:250) and anti-ZO-1 (1:250). After washing,
membranes were incubated for 1 h with peroxidase-con-
jugated goat anti-rabbit IgG (1:10,000) or peroxidase-
conjugated goat anti-mouse IgG (1:40,000). Proteins were
visualized using an enhanced chemiluminescence kit
(Amersham Pharmacia Biotech, Buckingham, UK). Band
images were quantified by optical density using the Lab-
Works 4.6 software (BIO RAD, Upland, CA).
Statistical analysis
Transepithelial Electric Resistance data were normalized
to percentage and analyzed by one-way ANOVA followed
by Bonferroni posttest for comparison between groups
using GraphPad Prism version 4.0 for Windows (Graph-
Pad Software, San Diego, CA). Densitometric analyses,
which are comparisons between non-treated (which was
normalized to 1) and treated samples, were carried out
using Student's t-test. All values in text and figures are
means ± S.E.M of three independents experiments. Signif-
icantly different: * (P < 0.05).
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